Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics (Nasdaq: RLAY) will participate in two fireside chats this March.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY) will participate in two fireside chats this March. The first event is at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 10:30 a.m. ET, and the second is the Barclays Global Healthcare Conference on March 15, 2023, at 4:05 p.m. ET. Both events will be available for live webcasting on Relay Therapeutics’ website under the Events section. Archived replays will be accessible for up to 30 days after each chat. Relay Therapeutics is a clinical-stage precision medicine company focused on innovative drug discovery using its Dynamo™ platform.
Details
News Market Reaction – RLAY
The recorded move for RLAY in the trading session of this news was -0.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month, at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET and the Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 4:05 p.m. ET.
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcasts will be available for up to 30 days following each event.
About Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Caroline Glen
617-370-8837
cglen@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.